SCHOTT has decided to invest a sum of 70 million euros as it expands its Indian tubing site in Jambusar, in Gujarat.

"Against the backdrop of the growth trend in the Indian pharmaceutical business and the pandemic, we want to commit to secure the supply of pharma glass," explains Dr. Patrick Markschläger, Executive Vice President of SCHOTT's Business Unit Tubing.

In India, almost all approved vaccines are packed in FIOLAX glass made by SCHOTT. With additional melting tanks and production lines, SCHOTT intends to ensure that this Asian manufacturing hub can adequately supply high-quality pharma glass for the Indian pharma industry and neighbouring countries.

"The increase of over 30 per cent in the facility's overall Indian production capacity is at the same time a commitment to supporting the government's vision of India becoming a global pharmaceutical hub," adds Pawan Shukla, Managing Director SCHOTT Glass India, during the groundbreaking event at the site.

The additional tank is scheduled to go into operation at the beginning of 2023, with the second one following a year later. The expansion in Jambusar is part of a more than US $ 1 billion strategic investment program of SCHOTT through 2025, leveraging the global pharma tubing and packaging business.